Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Anti-SARS-CoV-2 Monoclonal Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (1) SARS-CoV (13)
By Research Areas:	Cancer (1) Infection (8) Inflammation/Immunology (6)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-P990756

Pemivibart	SARS-CoV	Inflammation/Immunology
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).

HY-P990766

Sipavibart AZD3152	SARS-CoV	Infection
Sipavibart (AZD3152) is a human IgG1 λ2 monoclonal antibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .

HY-P99347

Etesevimab CB 6; JS016	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .

HY-P9807

Anti-SARS-CoV-2 Spike mAb (CR3022) SARS-CR3022; SARS-CoV-2 Antibody-CR3022	SARS-CoV	Infection Inflammation/Immunology
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .

HY-P990768

Timcevibart	SARS-CoV	Inflammation/Immunology
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990705

Gorivitug REGN-15160	SARS-CoV	Inflammation/Immunology
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990725

Nisfevitug	SARS-CoV	Inflammation/Immunology
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991170

Ibramvibart	SARS-CoV	Infection
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990711

Canrivitug	SARS-CoV	Inflammation/Immunology
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-145644

Ogalvibart C-135-LS; BMS-986414	SARS-CoV	Infection Cancer
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an **anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2** spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-145643

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an **anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2** spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

Cat. No.	상품명	Target	Research Area	Image

HY-P990756

Pemivibart	SARS-CoV	Inflammation/Immunology
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).

HY-P990766

Sipavibart AZD3152	SARS-CoV	Infection
Sipavibart (AZD3152) is a human IgG1 λ2 monoclonal antibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .

HY-P99347

Etesevimab CB 6; JS016	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .

HY-P9807

Anti-SARS-CoV-2 Spike mAb (CR3022) SARS-CR3022; SARS-CoV-2 Antibody-CR3022	SARS-CoV	Infection Inflammation/Immunology
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .

HY-P990768

Timcevibart	SARS-CoV	Inflammation/Immunology
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990705

Gorivitug REGN-15160	SARS-CoV	Inflammation/Immunology
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990725

Nisfevitug	SARS-CoV	Inflammation/Immunology
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991170

Ibramvibart	SARS-CoV	Infection
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990711

Canrivitug	SARS-CoV	Inflammation/Immunology
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-145644

Ogalvibart C-135-LS; BMS-986414	SARS-CoV	Infection Cancer
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an **anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2** spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-145643

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an **anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2** spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
이메일 *

	Sorry, but the email address you supplied was invalid.